Flagship Pioneering Announces Appointment of Raj Panjabi as Senior Partner
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Deutsche Bank Upgrades Moderna (MRNA) to Hold, 'a more troublesome Winter’s Tale, but up to Hold'
August 6, 2024 4:18 PM EDTDeutsche Bank analyst Emmanuel Papadakis upgraded Moderna (NASDAQ: MRNA) from Sell to Hold with a price target of $80.00 (from $85.00).
The analyst comments "We update after Q2s difficult print (Moderna: Q2 first take. Set to be pursued by many bears?*: winter reckoning arrives early (01/08/24)), which delivered the triple-blow of downgraded revenue, reduced gross margin and maintained... More
